HOWL · Werewolf Therapeutics, Inc.
$0.95
-0.02 (-2.53%)
At close · Aug 28
Going-concern doubt
— flagged Jul 31, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We believe there is substantial doubt about our ability to continue as a going concern for at least twelve months from the date that these condensed consolidated financial statements are issued in this Quarterly Report.”View the 10-Q filed Jul 31, 2026
Market Cap
$47.18M
Shares
48.60M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.97
Open$0.99
Day$0.91–1.00
52W close$0.31–2.19
Avg vol 30d13.6M
Short int1.1M · 2.2% float · 3.7d
Short vol44%
DataApr 2021–Aug 2026
Filing10-Q · Jul 31
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 31, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+49%
above
Price vs 50-day avg
+124%
above
RSI (14)
86
overbought
MACD trend
Positive
52-week position
35%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+94%
trailing
6-month return
+54%
trailing
YTD return
+53%
this year
Relative strength
+39%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +9 funds added
Insider flow
Distributing
Net -$573.2K over 90 days · 100% sells
Short interest
Falling
2.20% of float · ▼ -2.9% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
46 holders — mid 3-yr range
Squeeze score
75
high risk · 0–100
Fundamentals
EPS growth
+18%
Y/Y
Free cash flow
$-60.3M
Balance sheet
$25.0M
net cash
Quant / Vol
risk profile
Volatility
147%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
9.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+49%
Bullish
Price vs 50-day avg
+124%
Bullish
RSI (14)
86
Bearish
MACD trend
Positive
Bullish
52-week position
35%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +9 funds added
Insider flow
Distributing
Net -$573.2K over 90 days · 100% sells
Short interest
Falling
2.20% of float · ▼ -2.9% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
46 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $1 · 35%
Range high $2
vs 200-day avg +49%
vs 50-day avg +124%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HOWL
this stock
Werewolf Therapeutics, Inc.
|
$47.18M | +53.1% | — | — | 2.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.8% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +4.6% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +25.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HOWL | +125.2% | +94.0% | +53.6% | +175.0% | +53.1% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | +124.1% | +90.0% | +38.9% | +171.8% | +40.0% |